OnlineSemaglutide.org

What OnlineSemaglutide.org does

OnlineSemaglutide.org is a direct-to-consumer telehealth platform operated by Pacific Shores Research Group, LLC, a California corporation headquartered in San Diego. Founded in July 2025, the company connects patients seeking GLP-1 weight loss medications with U.S.-licensed clinicians via a 100% online intake and consultation process, routing prescriptions to a network of FDA-registered 503A compounding pharmacies (Casa, Polomar, Perfectrx, Evoluciona) for fulfillment and home delivery. The product portfolio spans compounded semaglutide (injectable and oral), compounded tirzepatide (injectable and oral), and liraglutide injectable, with a starting price of $150/month for compounded semaglutide and $241/month for compounded tirzepatide under a flat monthly subscription model that does not charge higher prices as dosages increase. Back-office operations including intake, scheduling, telehealth consultation, prescription routing, and billing are handled by partner CareValidate Incorporated via its CareGLP platform, while clinical services are provided by Lion MDs, an independent medical practice with providers licensed in all 50 U.S. states.

The business model is a recurring B2C subscription without insurance billing, with revenue derived from monthly medication fees plus separate non-refundable medical consultation fees. The platform reports serving over 500,000 patients across all 50 U.S. states and is HIPAA-compliant, LegitScript-certified, and operates on a small 1-10 employee team. Marketing is conducted through SEO and content-driven direct-to-consumer channels, with patient acquisition occurring via the online assessment form at start.onlinesemaglutide.org. The platform acknowledges that compounded GLP-1 medications are not FDA-approved and are distinct from the brand-name products, positioning compounded access during national shortages as the core value proposition.

The company's structural design separates marketing (Pacific Shores Research Group), clinical operations (Lion MDs), and platform/billing operations (CareValidate), which is a common partnership-stack arrangement in the compounded telehealth space. Distribution is entirely self-serve and digital, with no physical clinic footprint. Operational scale signals (500,000+ patients, 50-state coverage) indicate ambitious positioning, though the early founding date, small disclosed headcount, and absence of disclosed funding or revenue figures constrain the ability to verify the underlying scale of the active subscriber base.

Name

OnlineSemaglutide.org

Legal name

Pacific Shores Research Group, LLC

Website

https://onlinesemaglutide.org

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

OnlineSemaglutide.org is a direct-to-consumer telehealth platform, founded July 2025 and operated by Pacific Shores Research Group, LLC, that connects adults seeking weight loss treatment with U.S.-licensed clinicians and compounds GLP-1 medications (semaglutide, tirzepatide, liraglutide) via 503A pharmacies across all 50 U.S. states.

Ownership category

akta.pro rank

Product category

Telehealth Weight Loss Services

NAICS

Ambulatory Health Care Services (621)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA)

Keywords

• Telehealth weight loss
• Compounded GLP-1 medications
• Semaglutide prescriptions
• Tirzepatide prescriptions
• Online medical consultations

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Monthly Medication Subscription: Recurring monthly subscription model for compounded GLP-1 medications. All dosages cost the same with no upcharges as patients progress through treatment. No insurance needed.
2. Medical Consultation Fees: Fees charged by medical providers for telehealth consultations and healthcare services. Medical consult fees are not subject to or eligible for refund.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

OnlineSemaglutide.org operates a direct-to-consumer telehealth platform that connects patients in all 50 U.S. states with licensed clinicians who evaluate eligibility and prescribe compounded GLP-1 weight loss medications (semaglutide, tirzepatide, and liraglutide). When a prescription is appropriate, it is routed to FDA-registered 503A compounding pharmacies in the company's network for fulfillment and home delivery. The platform provides ongoing provider-supervised care, dose adjustments, and 1-on-1 telehealth support without requiring any in-person clinic visits or insurance.

Product overview

OnlineSemaglutide.org is a telehealth platform offering access to compounded GLP-1 weight loss medications. The company operates two main product lines: Compounded Semaglutide (available as injectable and oral forms, starting at $150/month) and Compounded Tirzepatide (injectable and oral forms, starting at $241/month), plus Liraglutide Injectable. All medications are prepared by independently licensed 503A compounding pharmacies (Casa, Polomar, Perfectrx, and Evoluciona) in the company's network. The platform connects patients with U.S.-licensed clinicians via telehealth for consultation, prescription, and ongoing care management.

Differentiator

Problem solved

Functional benefit

Products and services

• Compounded Semaglutide (Injectable) Compounded injectable semaglutide medication for weight loss, the most common starting medication offered, starting at $150/month. Contains the same active ingredient as FDA-approved semaglutide, prepared by FDA-registered 503A compounding pharmacies.
• Compounded Semaglutide (Oral) Oral tablet form of compounded semaglutide offering a needle-free alternative for weight loss treatment, delivered through the monthly subscription program.
• Compounded Tirzepatide (Injectable) Compounded injectable tirzepatide medication, a dual-action GLP-1/GIP receptor agonist starting at $241/month. Marketed for potentially stronger appetite control and faster progress versus semaglutide.
• Compounded Tirzepatide (Oral) Oral tablet form of compounded tirzepatide offering a needle-free alternative for weight loss treatment, delivered through the monthly subscription program.
• Liraglutide Injectable Injectable GLP-1 medication for weight loss offered as part of the medication portfolio alongside semaglutide and tirzepatide products.

Quantifiable outcome

• Average ~15% body weight reduction in clinical trials with semaglutide (2.4 mg)
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CareValidate IncorporatedcoreImplementation/ SI/ Consulting PartnerPartner operating intake, scheduling, telehealth consultation, prescription routing, and billing services on the CareGLP platform. Handles the patient management system from consultation initiation through billing and fulfillment coordination.
• Lion MDscoreStrategic or Co-development PartnerIndependent medical practice providing clinicians licensed in all 50 U.S. states for telehealth consultations and prescription services.
• Casa PharmacycoreOthers503A Licensed compounding pharmacy in the network that prepares patient-specific GLP-1 medications under USP-797 sterile compounding standards.
• Polomar PharmacycoreOthers503A Licensed compounding pharmacy in the network that prepares patient-specific GLP-1 medications under USP-797 sterile compounding standards.
• Perfectrx PharmacycoreOthers503A Licensed compounding pharmacy in the network that prepares patient-specific GLP-1 medications under USP-797 sterile compounding standards.
• Evoluciona PharmacycoreOthers503A Licensed compounding pharmacy in the network that prepares patient-specific GLP-1 medications under USP-797 sterile compounding standards.
• StripecoreOthersPayment processor for secure credit card transaction processing. Cookies assist in detecting and preventing fraud.
• Intuit QuickbooksminorOthersPayment processor and financial management tool for business transaction processing.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ro: Vertically integrated DTC telehealth platform offering weight management programs with GLP-1 medications. Competes in the same cash-pay, online-intake, clinician-prescribed medication fulfillment space as OnlineSemaglutide.org.
• LifeMD: DTC telehealth company with significant weight management and GLP-1 prescribing operations. Operates under a similar cash-pay subscription model with online consultations and direct-to-patient prescription fulfillment.
• Henry Meds: Smaller DTC telehealth platform focused specifically on compounded GLP-1 weight loss medications via online consultation and home delivery. Closest niche-comparable competitor to OnlineSemaglutide.org in product and pricing model.
• Strut Health: DTC telehealth platform offering compounded semaglutide and tirzepatide for weight loss via online consultations and pharmacy fulfillment. Operates in the same cash-pay subscription niche with similar patient acquisition funnels.
• Hims & Hers Health: Public DTC telehealth platform that has rapidly scaled into GLP-1 weight loss alongside its core men's/women's health offerings. Directly comparable business model: cash-pay subscriptions, online intake, clinician-prescribed medications, and home delivery.

Broad incumbents

• Teladoc Health: Large incumbent virtual care platform offering telehealth consultations across many conditions. While not specifically focused on compounded GLP-1 weight loss, it operates in the same DTC telehealth delivery model and competes for similar patient demand.
• Eli Lilly (LillyDirect): Manufacturer of branded tirzepatide (Mounjaro/Zepbound) that has launched a direct-to-patient pharmacy channel. Comparable cash-pay distribution model but with FDA-approved product and manufacturer economics, putting potential pricing pressure on compounded platforms.

Emerging players

• Noom: Behavior-change platform that has expanded into clinician-prescribed GLP-1 medications via Noom Med. Comparable patient base seeking weight management, though Noom's primary differentiator remains its app-based coaching rather than compounding.
• Found: DTC weight management platform that combines clinician-prescribed medication (including GLP-1s) with behavior change coaching. Comparable in cash-pay, online-first delivery model but with a stronger coaching/lifestyle component.

Others

• WeightWatchers (WW):

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights5 records

Customer concentration

• Xx.com/onlinesemagluti
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/onlinesemaglutide

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OnlineSemaglutide.org